Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Weigong Zhou(Epidemic Intelligence Service), Robert T. Chen(The Task Force for Global Health), Susan S. Ellenberg(University of Pennsylvania), Roseanne English-Bullard, Robert Ball(Center for Drug Evaluation and Research), John K. Iskander, Vitali Pool, Robert Pless, Penina Haber, Robert P. Wise(Center for Biologics Evaluation and Research), M. Miles Braun(Center for Biologics Evaluation and Research), Gina T. Mootrey
PubMed
January 24, 2003
Cited by 397
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Effects of Testosterone Treatment in Older Men
|New England Journal of Medicine|2016|864
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448